EAST AFRICAN COMMUNITY
EAST AFRICAN COMMUNITY COMPETITION AUTHORITY

P.O. Box 1096
ARUSHA, TANZANIA

Tel: +255 27 2162100
Mob: +255 752 899151
Fax: +255 27 2162190
E-mail: eacca@eachq.org
Web: http://www.eacompetition.org

EAC COMPETITION AUTHORITY MERGER INQUIRY NOTICE *NO. 16* OF 2026. THE PROPOSED TRANSACTION BETWEEN SHALINA HEALTHCARE LIMITED AND DINLAS PHARMA (AFRICA) LIMITED

It is hereby notified in terms of Regulation 8 of the EAC Competition (Mergers and Acquisitions) Regulations, 2025 (the Regulations) that the EAC Competition Authority (the Authority) after receiving a notification in terms of Section 11 of the East African Community Competition Act, 2006 (the Act) involving Shalina Healthcare Limited (SHALINA) and Dinlas Pharma (Africa) Limited (DINLAS) intends to embark on an inquiry in terms of Part IV of the Act and Part III of the Regulations.

The Proposed Transaction concerns the acquisition by the Acquiring Undertaking (the Acquirer), Shalina Healthcare Limited of 100% of the issued share capital of the Target undertaking (the Target), Dinlas Pharma and its subsidiary Taurus Export Processing Zone Limited (**Taurus**) from Bliss Healthcare Holdings Limited (the **Seller**). Accordingly, upon implementation of the Proposed Transaction, the Acquirer will acquire sole control of the Target and, indirectly Taurus.

The Parties submitted that the Acquirer is a private company registered in the Isle of Man and forms part of the Shalina Group (the **Acquirer Group**). Within the Community, the Acquirer Group is present in the Democratic Republic of Congo, Kenya and South Sudan through in-country subsidiaries, and its products are made available in Somalia indirectly through independent third-party distributors.

The Acquirer Group manufactures, markets and distributes pharmaceutical and healthcare products. Its EAC activities include those of Shalina Healthcare Kenya Limited (**SHKL**), which supplies and distributes pharmaceutical products in Kenya; Provexa Pharma Kenya Limited (**Provexa**), an investment holding company; Orange Pharma Limited (**Orange Pharma**), which leases commercial property; Shalina Healthcare SARL, which markets and distributes pharmaceutical products in the Democratic Republic of Congo; and Shalina Pharmacy Limited, which markets and distributes pharmaceutical products in South Sudan. Sonal Holdings Uganda Ltd (**Sonal Holdings**), the registered owner of certain pharmaceutical products, and Shalina Healthcare SURL (Burundi) are dormant and are not trading. The Acquirer Group's products are made available in Burundi only through independent third-party distributors, and only in product categories outside the anti-infective, analgesics and anti-inflammatory, gastro-intestinal and respiratory categories.

Further, the Parties submitted that the target is a private company incorporated in the Republic of Kenya and formerly known as Dinlas Pharma EPZ Limited. The Target and Taurus Export Processing Zone Limited are together referred to as the **Target Group**. Taurus is a wholly owned subsidiary of Dinlas and a property holding company. The Target Group manufactures, distributes and exports pharmaceutical products from Kenya, including tablets, syrups, suspensions, creams and ointments and dietary supplements. The Target Group supplies Kenya and exports directly to Burundi, Tanzania and Somalia and indirectly to the Democratic Republic of Congo, Tanzania, Uganda and South Sudan through third-party local distributors.

The Authority shall, in accordance with the provisions of the Act and Regulations, determine, among other things, whether or not the merger is likely to substantially lessen competition within the Community or is contrary to the public interest. In view of this, the Authority hereby gives notice to all interested stakeholders, including competitors, suppliers and customers of the

merging parties to submit written representations to the Authority with regard to the subject matter of the proposed inquiry by emailing them to: eacca@eachq.org and vokoth@eachq.org. All written representations should be sent to the Authority not later than 13th December, 2026.

If you wish to seek further details and/ or clarifications on any aspect of this proposed transaction or need assistance, you may get in touch with the Deputy Registrar, Mergers and Acquisitions, Mr. Vincent Okoth on +255 27 216 2100 or via email at vokoth@eachq.org

All written representations submitted to the Authority will be treated with the strictest confidentiality and will only be used for the purpose of this inquiry.